Taurolidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Taurolidine is an antimicrobial derivative of taurine used for prophylaxis of catheter-related infections.

Generic Name
Taurolidine
DrugBank Accession Number
DB12473
Background

Taurolidine has been investigated for the prevention of Central Venous Catheter, Home Parenteral Nutrition, and Catheter-Related Infections.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 284.35
Monoisotopic: 284.061297359
Chemical Formula
C7H16N4O4S2
Synonyms
  • Taurolidine
External IDs
  • W-3100M

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Taurolidine.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Taurolidine.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Taurolidine.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Taurolidine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
B05CA05 — Taurolidine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as thiadiazinanes. These are organic heterocyclic compounds containing a six-membered saturated heterocycle with two nitrogen, one sulfur, and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiadiazinanes
Sub Class
Not Available
Direct Parent
Thiadiazinanes
Alternative Parents
Organosulfonamides / Organic sulfonamides / Azacyclic compounds / Aminals / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aliphatic heteromonocyclic compound / Aminal / Azacycle / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfonic acid amide / Organic sulfonic acid or derivatives / Organonitrogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
8OBZ1M4V3V
CAS number
19388-87-5
InChI Key
AJKIRUJIDFJUKJ-UHFFFAOYSA-N
InChI
InChI=1S/C7H16N4O4S2/c12-16(13)3-1-10(5-8-16)7-11-2-4-17(14,15)9-6-11/h8-9H,1-7H2
IUPAC Name
4-[(1,1-dioxo-1lambda6,2,4-thiadiazinan-4-yl)methyl]-1lambda6,2,4-thiadiazinane-1,1-dione
SMILES
O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1

References

General References
Not Available
PubChem Compound
29566
PubChem Substance
347828711
ChemSpider
27486
ChEBI
135173
ChEMBL
CHEMBL2105420
ZINC
ZINC000019322537
Wikipedia
Taurolidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionCentral Venous Catheterization / Parenteral Nutrition, Home1
4Unknown StatusPreventionCatheter Related Infections1
4Unknown StatusPreventionHemodialysis Catheter Infection / Thrombosis; Dialysis Catheter1
3CompletedPreventionCatheter Related Infections / Renal Failure, Chronic Renal Failure1
3CompletedPreventionInfection / Parenteral Nutrition / Septic1
3CompletedTreatmentInfection / Patency1
2CompletedTreatmentPeriodontitis1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentFallopian Tubes Cancer / Ovarian Cancer / Primary Peritoneal Cavity Cancer1
1, 2CompletedTreatmentPeriodontitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionIntraperitoneal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility16.2 mg/mLALOGPS
logP-2.1ALOGPS
logP-2.5ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)10.53ChemAxon
pKa (Strongest Basic)1.97ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.82 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity60.73 m3·mol-1ChemAxon
Polarizability26.08 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 22:31 / Updated on May 27, 2021 02:58